Beware of Striking Medical Studies

A large-scale statistical analysis shows that medical studies revealing “very large effects” seldom stand up when other researchers try to replicate them.

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Wikimedia, BmramonClinical trials that find very large effects for medical treatments tend not to hold up under further scrutiny, according a study published this week (October 24) in the Journal of the American Medical Association. The authors say the findings should be a reminder to be cautious about exciting early studies.

Analyzing data from 230,000 clinical trials across various disciplines, a team led by Stanford University epidemiologist John Ioannadis found that researchers rarely succeed in replicating study results that claimed a “very large effect.” “The effects largely go away; they become much smaller,” Ioannidis told the Los Angeles Times. “It's likely that most interventions that are effective have modest effects.”

The analysis also revealed that studies reporting outstanding results tended to have used fewer than 100 subjects, so the effects are more likely to be influenced by chance. Moreover, “very large effect” studies usually measure intermediate effects, such as whether statins reduce LDL cholesterol in the blood, rather than more meaningful outcomes like the incidence of disease or death.

The authors suggest that the results should ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Dan Cossins

    This person does not yet have a bio.
Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo